Bob Li
MD, PhD, MPH
Thoracic Oncologist
👥Biography 个人简介
Bob Li at Memorial Sloan Kettering focuses on targeted therapy for lung cancer, particularly overcoming resistance to first-generation ROS1 and NTRK inhibitors. He was a key investigator on the TRIDENT-1 trial of repotrectinib for ROS1 and NTRK fusion-positive NSCLC. His research defines mechanisms of acquired resistance and next-generation inhibitor strategies.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Bob Li 的研究动态
Follow Bob Li's research updates
留下邮箱，当我们发布与 Bob Li（Memorial Sloan Kettering Cancer Center）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment